| 7 | Glioblastoma & Astrocytoma | 149 | mEHT + radiotherapy + chemotherapy (BSC, palliative range) | 5y-OS = 83% (AST) in mEHT vs. 5y-OS = 25% by BSC. 5y-OS = 3.5% in mEHT vs. 5y-OS = 1.2% by BSC for GBM. Median OS = 14 m of mEHT for GBM and OS = 16.5 m for AST. | Fiorentini, Sarti, et al. 2019b [149] |
| 8 | Advanced hepatocell. carcinoma | 21 | Chemotherapy + mEHT | PR = 1, CR = 0, SD = 11. Combined therapy was effective, and no major complications were observed. | Gadaleta-Caldarola, et al. 2014 [150] , |
| 9 | Refractory hepatocell. carcinoma | 22 | mEHT + thermo-active agents (TAA) or mEHT without TAA | CR = 1, PR = 0. Median OS = 20.5 weeks. 50% showed evidence of increasing QoL and minimal toxicity. | Ferrari, Ponti et al. 2007 [151] |
| 10 | Small-cell lung cancer (SCLC) | 22 | Chemotherapy + mEHT | mEHT enhanced destroying the cancer cells. Improved the OS of patients too. | Lee, Haam et al. 2013 [152] |
| 11 | Advanced cervical cancer | 236 | Random. Phase III (chemoradiation alone (CHR) and mEHT group (mEHT + CHR) [preliminary data] | Preliminary data for first 100 participants. A positive trend in survival and local disease control by mEHT. No significant differences in acute adverse events or quality of life between the groups. | Minnaar, Baeyens et al. 2016 [153] |
| 12 | Advanced cervical cancer | 38 | Chemotherapy + /− mEHT | The overall response (CR + PR + SD vs. PD) to was significantly greater with mEHT. No complications or extra adverse effect by mEHT. | Lee, Lee et al. 2017 [136] |
| 13 | Advanced cervical cancer | 72 | Radiotherapy + chemotherapy + mEHT | CR + PR = 73.5%; SD = 14.7%. The addition of mEHT increased the QoL and OS. | Pesti, et al. 2013 [139] |
| 14 | Advanced cervical carcinoma | 20 | mEHT + radiotherapy + chemotherapy | mEHT increases the peri-tumour temperature and blood flow in human cervical tumours, promoting the radiotherapy + chemotherapy. | Lee, Kim, et al. 2018 [154] |
| 15 | Advanced cervical carcinoma | 108 | mEHT + chemoradiotherapy | The metabolicly complete remnission (CMR) of disease outside the radiation field at 6 m post-treatment shows abscopal effect, significantly associated with the addition of mEHT. | Minnaar, Kotzen, et al. 2020b [155] |
| 16 | Advanced cervical carcinoma | 206 | Random. Phase III (chemoradiation alone (CHR) and mEHT group (mEHT + CHR) [preliminary data] | Compliance to mEHT treatment was high (97% completed ≥8 treatments) with no significant differences in CRT-related toxicity between treatment groups or between HIV-positive and -negative participants. | Minnaar, Kotzen, et al. 2020a [156] |
| 17 | Advanced cervical carinoma | 202 | mEHT + chemoradiotherapy | Six month local disease-free survival (LDFS) = 38.6% for mEHT and LDFS = 19.8% without mEHT (p = 0.003). Local disease control (LDC) = 45.5% with mEHT LDC = 24.1% without mEHT; (p = 0.003). | Minnaar, Kotzen, et al. 2019 [157] |
| 18 | Stage III-IV NSCLC | 15 | Ascorbic acid (AA) infusion + mEHT | AA safely synergies with mEHT and well tolerated, no major adverse effects | Ou, Zhu, et al. 2017 [158] , |
| 19 | Advanced NSCLC | 97 | mEHT + radiotherapy + chemotherapy | Median OS = 9.4 m with mEHT OS = 5.6 m without mEHT; (p < 0.0001). Median PFS = 3 m for mEHT and PFS = 1.85 m without mEHT; p < 0.0001. | Ou, Zhu, et al. 2020 [159] |
| 20 | Advanced NSCLC | 311 (61 + 197 + 53) | Radiotherapy + chemotherapy + mEHT | Two centres PFY (n = 61), HTT (n = 197) control (n = 53). 80% (PFY), 80% (HTT) had distant metastases, conventional therapies failed. Median OS = 16.4 m (PFY), 15.6 m (HTT), 14 m (control); 1st y survival 67.2% (PFY), 64% (HTT), 26.5% (control). | Dani, Varkonyi, et al. 2011 + Szasz, 2014b [160] |